Literature DB >> 25797312

Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales.

K Haralambos1, S D Whatley2, R Edwards2, R Gingell2, D Townsend2, P Ashfield-Watt1, P Lansberg3, D B N Datta2, I F W McDowell4.   

Abstract

BACKGROUND/
OBJECTIVE: Familial Hypercholesterolaemia (FH) is caused by mutations in genes of the Low Density Lipoprotein (LDL) receptor pathway. A definitive diagnosis of FH can be made by the demonstration of a pathogenic mutation. The Wales FH service has developed scoring criteria to guide selection of patients for DNA testing, for those referred to clinics with hypercholesterolaemia. The criteria are based on a modification of the Dutch Lipid Clinic scoring criteria and utilise a combination of lipid values, physical signs, personal and family history of premature cardiovascular disease. They are intended to provide clinical guidance and enable resources to be targeted in a cost effective manner.
METHODS: 623 patients who presented to lipid clinics across Wales had DNA testing following application of these criteria.
RESULTS: The proportion of patients with a pathogenic mutation ranged from 4% in those scoring 5 or less up to 85% in those scoring 15 or more. LDL-cholesterol was the strongest discriminatory factor. Scores gained from physical signs, family history, coronary heart disease, and triglycerides also showed a gradient in mutation pick-up rate according to the score.
CONCLUSION: These criteria provide a useful tool to guide selection of patients for DNA testing when applied by health professionals who have clinical experience of FH.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cholesterol; Criteria; Diagnosis; Familial Hypercholesterolaemia; Genetics

Mesh:

Substances:

Year:  2015        PMID: 25797312     DOI: 10.1016/j.atherosclerosis.2015.03.003

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  25 in total

1.  Variability in assigning pathogenicity to incidental findings: insights from LDLR sequence linked to the electronic health record in 1013 individuals.

Authors:  Maya S Safarova; Eric W Klee; Linnea M Baudhuin; Erin M Winkler; Michelle L Kluge; Suzette J Bielinski; Janet E Olson; Iftikhar J Kullo
Journal:  Eur J Hum Genet       Date:  2017-02-01       Impact factor: 4.246

Review 2.  The panorama of familial hypercholesterolemia in Latin America: a systematic review.

Authors:  Roopa Mehta; Rafael Zubirán; Alexandro J Martagón; Alejandra Vazquez-Cárdenas; Yayoi Segura-Kato; María Teresa Tusié-Luna; Carlos A Aguilar-Salinas
Journal:  J Lipid Res       Date:  2016-10-24       Impact factor: 5.922

Review 3.  Strategies for screening for familial hypercholesterolaemia in primary care and other community settings.

Authors:  Nadeem Qureshi; Maria Luisa R Da Silva; Hasidah Abdul-Hamid; Stephen F Weng; Joe Kai; Jo Leonardi-Bee
Journal:  Cochrane Database Syst Rev       Date:  2021-10-07

Review 4.  My Approach to the Patient With Familial Hypercholesterolemia.

Authors:  Maya S Safarova; Iftikhar J Kullo
Journal:  Mayo Clin Proc       Date:  2016-06       Impact factor: 7.616

5.  Elevated lipoprotein(a) and familial hypercholesterolemia in the coronary care unit: Between Scylla and Charybdis.

Authors:  Katrina L Ellis; Jing Pang; David Chieng; Damon A Bell; John R Burnett; Carl J Schultz; Graham S Hillis; Gerald F Watts
Journal:  Clin Cardiol       Date:  2018-02-26       Impact factor: 2.882

6.  Lipoprotein(a) level associates with coronary artery disease rather than carotid lesions in patients with familial hypercholesterolemia.

Authors:  Di Sun; Bing-Yang Zhou; Xi Zhao; Sha Li; Cheng-Gang Zhu; Yuan-Lin Guo; Ying Gao; Na-Qiong Wu; Geng Liu; Qian Dong; Jian-Jun Li
Journal:  J Clin Lab Anal       Date:  2018-03-30       Impact factor: 2.352

Review 7.  Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care.

Authors:  Gerald F Watts; Samuel S Gidding; Pedro Mata; Jing Pang; David R Sullivan; Shizuya Yamashita; Frederick J Raal; Raul D Santos; Kausik K Ray
Journal:  Nat Rev Cardiol       Date:  2020-01-23       Impact factor: 32.419

8.  Improving the yield of genetic testing in familial hypercholesterolaemia.

Authors:  Ezim Ajufo; Marina Cuchel
Journal:  Eur Heart J       Date:  2017-02-21       Impact factor: 35.855

Review 9.  Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors.

Authors:  Ivan Pećin; Merel L Hartgers; G Kees Hovingh; Ricardo Dent; Željko Reiner
Journal:  Eur J Prev Cardiol       Date:  2017-06-23       Impact factor: 7.804

Review 10.  Genetic Architecture of Familial Hypercholesterolaemia.

Authors:  Mahtab Sharifi; Marta Futema; Devaki Nair; Steve E Humphries
Journal:  Curr Cardiol Rep       Date:  2017-05       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.